LUNG CANCER

The lungs are a pair of cone-shaped breathing organs inside the chest. The lungs bring oxygen into the body when breathing in and send carbon dioxide out of the body when breathing out. Each lung has sections called lobes. Two tubes called bronchi lead from the trachea (windpipe) to the lungs.

The two main types of lung cancer are non-small cell lung cancer and small cell lung cancer. The types are based on the way the cells look under a microscope. Non-small cell lung cancer is much more common than small cell lung cancer.

Tobacco smoking is the most common cause of lung cancer. Lung cancer is the leading cause of death from cancer in the U.S. and the number of deaths from lung cancer in women is increasing. For most patients with lung cancer, current treatments do not cure the cancer.

Contact Details

IKRIS Pharma Network Pvt. Ltd.
905 , I - Thum Business Park,
Plot No. A-40, Unit No. 5, Tower A,
Sector-62, Noida – 201301 (India)

Phone No.- +91-120–2400370.
M: + 91 8130290915

WhatsApp: +91 8130290915
QQID:- 1927411523
Skype ID: praveen.sikri
E:info@ikrispharmanetwork.com

Query Form

LUNG CANCER MEDICATIONS

Navelbine® (Vinorelbine Tartrate)

NAVELBINE is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced nonsmall cell lung cancer (NSCLC).

More Details

Ofev (nintedanib) Capsules

OFEV is a prescription medicine used to treat people with a lung disease called idiopathic pulmonary fibrosis (IPF). It is not known if OFEV is safe and effective in children.

Learn More

Nplate (romiplostim)

Nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

Learn More

Opdivo (nivolumab) injection

OPDIVO is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.

Learn More

Keytruda 50 mg/vial Prembrolizumab for injection

KEYTRUDA®(pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma

Learn More

TAGRISSO™ (osimertinib) tablet

TAGRISSO is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test,

Learn More